The role of Alzheimer's and cerebrovascular pathology in mediating the effects of age, race, and Apolipoprotein E genotype on dementia severity in pathologically-confirmed Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 49, Issue 2, 2015, Pages 531-545

  Gavett, Brandon E ^a   John, Samantha E ^a   Gurnani, Ashita S ^a   Bussell, Cara A ^a   Saurman, Jessica L ^a  

^a Department of Psychology ^*  (United States)

Author keywords

Aging; Alzheimer's disease; apolipoprotein E2; apolipoprotein E4; dementia; vascular dementia

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGE; AGED; ALLELE; ALZHEIMER DISEASE; APOE EPSILON2 GENE; APOE EPSILON4 GENE; ARTICLE; CEREBROVASCULAR DISEASE; DISEASE SEVERITY; FEMALE; GENE; GENOTYPE; HUMAN; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; RACE; AGING; ANCESTRY GROUP; COMPLICATION; DEMENTIA; EDUCATIONAL STATUS; ETHNOLOGY; GENETICS; MENTAL HEALTH; MIDDLE AGED; PATHOLOGY; THEORETICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CEREBROVASCULAR DISORDERS; CONTINENTAL POPULATION GROUPS; DEMENTIA; EDUCATIONAL STATUS; FEMALE; GENOTYPE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MODELS, THEORETICAL;

EID: 84948693741     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150252     Document Type: Article

References (75)

1. Leifer BP (2003) Early diagnosis of Alzheimer's disease: Clinical and economic benefits. J Am Geriatr Soc 51, S281-S288.
2. Kohler S, Hamel R, Sistermans N, Koene T, Pijnenburg YAL, Flier WM, van der, Scheltens P, Visser P-J, Aalten P, Verhey FRJ, Ramakers I (2013) Progression to dementia in memory clinic patients without dementia: A latent profile analysis. Neurology 81, 1342-1349.
3. Libon DJ, DrabickDAG, GiovannettiT, Price CC, BondiMW, Eppig J, Devlin K, Nieves C, Lamar M, Delano-Wood L, Nation DA, Brennan L, Au R, Swenson R (2014) Neuropsychological syndromes associated with Alzheimer's/vascular dementia: A latent class analysis. J Alzheimers Dis 42, 999-1014.
4. Royall DR, Palmer RF, O'Bryant SE (2012) Validation of a latent variable representing the dementing process. J Alzheimers Dis 30, 639-649.
5. Royall DR, Palmer RF (2012) Getting past 'g': Testing a new model of dementing processes in dementia. J Neuropsychiatry Clin Neurosci 24, 37-46.
6. Royall DR, Palmer RF (2013) Validation of a latent construct for dementia case-finding in Mexican-Americans. J Alzheimers Dis 37, 89-97.
7. Royall DR, Palmer RF, Taniguchi S, Okamura A, Nakamura K, Koumi H, Matsuoka T, KatoY, OgawaM, Fujimoto H, Shibata K, Nakaaki S, Mimura M, Fukui K, Narumoto J (2015) Greater than the sum of its parts:-, improves upon a battery's diagnostic performance. Neuropsychology 29, 683-692.
8. Gavett BE, Vudy V, Jeffrey M, John SE, Gurnani AS, Adams JW (2015) The latent dementia phenotype in the Uniform Data Set: Cross-validation and extension. Neuropsychology 29, 344-352.
9. O'Bryant SE, Lacritz LH, Hall J, Waring SC, ChanW, Khodr ZG, Massman PJ, Hobson V, Cullum CM (2010) Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. Arch Neurol 67, 746-749.
10. O'Bryant SE, Xiao G, Barber R, Reisch J, Hall J, Cullum CM, Doody R, Fairchild T, Adams P, Wilhelmsen K, Diaz-Arrastia R (2011) A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord 32, 55-62.
11. Royall DR, Palmer RF, Vidoni ED, Honea RA, Burns JM (2012) The default mode network and related right hemisphere structures may be the key substrates of dementia. J Alzheimers Dis 32, 467-478.
12. Royall DR, Palmer RF (2014) Does ethnicity moderate dementia's biomarkers? Neurobiol Aging 35, 336-344.
13. Royall DR, Palmer RF (2014) Ethnicity moderates dementia's biomarkers. J Alzheimers Dis 43, 275-287.
14. Craft S (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch Neurol 66, 300-305.
15. Jellinger KA, Attems J (2007) Neuropathological evaluation of mixed dementia. J Neurol Sci 257, 80-87.
16. Kalaria RN (2000) The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 21, 321-330.
17. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, HofmanA(2000) Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S4-S9.
18. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann Neurol 45, 358-368.
19. Paternico D, Galluzzi S, Drago V, Bocchio-Chiavetto L, Zanardini R, Pedrini L, Baronio M, Amicucci G, Frisoni GB (2012) Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. Alzheimers Dement 8, 520-527.
20. Kovacs GG, Milenkovic I, Wohrer A, Hoftberger R, Gelpi E, Haberler C, Honigschnabl S, Reiner-Concin A, Heinzl H, Jungwirth S, Krampla W, Fischer P, Budka H (2013) Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: A community-based autopsy series. Acta Neuropathol 126, 365-384.
21. Erten-Lyons D, Dodge HH, Woltjer R, Silbert LC, Howieson DB, Kramer P, Kaye JA (2013) Neuropathologic basis of ageassociated brain atrophy. JAMA Neurol 70, 616-622.
22. Yu L, Boyle PA, Leurgans S, Schneider JA, BennettDA(2014) Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiol Aging 35, 819-826.
23. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ (2013) Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the national Alzheimer's coordinating centre. Brain 136, 2697-2706.
24. Pantoni L (2002) Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis 13, 7-10.
25. Erten-Lyons D, Woltjer R, Kaye J, Mattek N, Dodge HH, Green S, Tran H, Howieson DB, Wild K, Silbert LC (2013) Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 81, 977-983.
26. Kim H, Al-Shahi Salman R, McCulloch CE, Stapf C, Young WL (2014) Untreated brain arteriovenous malformation: Patient-level meta-Analysis of hemorrhage predictors. Neurology 83, 590-597.
27. Mehta KM, Yaffe K, Perez-Stable EJ, Stewart A, Barnes D, Kurland BF, Miller BL (2008) Race/ethnic differences in AD survival in US Alzheimer's disease centers. Neurology 70, 1163-1170.
28. Wilkins CH, Grant EA, Schmitt SE, McKeel DW, Morris JC (2006) The neuropathology of Alzheimer disease in African American and white individuals. Arch Neurol 63, 87-90.
29. Howard VJ, Kleindorfer DO, Judd SE, McClure LA, Safford MM, Rhodes JD, Cushman M, Moy CS, Soliman EZ, Kissela BM, Howard G (2011) Disparities in stroke incidence contributing to disparities in stroke mortality. Ann Neurol 69, 619-627.
30. Koch S, Gupta R, McClendon MS, Romano JG (2013) Racialethnic differences in lacunar infarction in a multiethnic stroke population. J Stroke Cerebrovasc Dis 22, 107-112.
31. Wolma J, Nederkoorn PJ, Goossens A, Vergouwen MDI, Schaik IN, van, Vermeulen M (2009) Ethnicity a risk factor? The relation between ethnicity and large-And small-vessel disease in White people, Black people, and Asians within a hospital-based population. Eur J Neurol 16, 522-527.
32. Howard VJ (2013) Reasons underlying racial differences in stroke incidence and mortality. Stroke 44, S126-S128.
33. Eisenstein M (2011) Genetics: Finding risk factors. Nature 475, S20-S22.
34. Rohn TT (2013) Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer's disease. Int J Mol Sci 14, 14908-14922.
35. Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9, 106-118.
36. Berg L, McKeelDW, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55, 326-335.
37. Broersen K, Rousseau F, Schymkowitz J (2010) The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: Oligomer size or conformation? Alzheimers Res Ther 2, 12.
38. Lehmann M, Ghosh PM, Madison C, Karydas A, Coppola G, O'Neil JP, Huang Y, Miller BL, Jagust WJ, Rabinovici GD (2014) Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positiveADpatients. J Neurol Neurosurg Psychiatry 85, 266-273.
39. Rohn TT, Day RJ, Sheffield CB, Rajic AJ, Poon WW (2014) Apolipoprotein E pathology in vascular dementia. Int J Clin Exp Pathol 7, 938-947.
40. Adluru N, Destiche DJ, Lu SY-F, Doran ST, Birdsill AC, Melah KE, Okonkwo OC, Alexander AL, Dowling NM, Johnson SC, Sager MA, Bendlin BB (2014) White matter microstructure in late middle-Age: Effects of apolipoprotein E4 and parental family history of Alzheimer's disease. Neuroimage Clin 4, 730-742.
41. Dorey E, Chang N, Liu QY, Yang Z, Zhang W (2014) Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease. Neurosci Bull 30, 317-330.
42. Niu W, Qi Y, Qian Y, Gao P, Zhu D (2009) The relationship between apolipoprotein E epsilon2/epsilon3/epsilon4 polymorphisms and hypertension: A meta-Analysis of six studies comprising 1812 cases and 1762 controls. Hypertens Res 32, 1060-1066.
43. FarrerLA(1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA 278, 1349-1356.
44. Talbot C, Lendon C, Craddock N, Shears S, Morris JC, Goate A (1994) Protection against Alzheimer's disease with apoE epsilon 2. Lancet 343, 1432-1433.
45. Betard C, RobitailleY, Gee M, Tiberghien D, Larrivee D, Roy P, Mortimer JA, Gauvreau D (1994) Apo E allele frequencies in Alzheimer's disease, Lewy body dementia, Alzheimer's disease with cerebrovascular disease and vascular dementia. Neuroreport 5, 1893-1896.
46. Feussner G, Piesch S, Dobmeyer J, Fischer C (1997) Genetics of type III hyperlipoproteinemia. Genet Epidemiol 14, 283-297.
47. Khan T, Shah T, Prieto D, Zhang W, Price J, Fowkes GR, Cooper J, Talmud PJ, Humphries SE, Sundstrom J, Hubacek J, Ebrahim S, Lawlor D, Ben-Shlomo Y, Abdollahi MR, Slooter AJC, Szolnoki Z, Sandhu M, Wareham N, Frikke-Schmidt R, Tybjærg-Hansen A, Fillenbaum G, Heijmans BT, Katsuya T, Gromadzka G, Singleton A, Ferrucci L, Hardy J, Worrall B, Rich SS, Matarin M, Whittaker J, Gaunt TR, Whincup P, Morris R, Deanfield J, Donald A, Davey Smith G, Kivimaki M, Kumari M, Smeeth L, Khaw K-D, Nalls M, Meschia J, Sun K, Hui R, Day I, Hingorani AD, Casas JP (2013) Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: Systematic review and meta-Analysis of 14, 015 stroke cases and pooled analysis of primary biomarker data from up to 60, 883 individuals. Int J Epidemiol 42, 475-492.
48. Brayne C, Ince PG, Keage HAD, McKeith IG, Matthews FE, Polvikoski T, Sulkava R (2010) Education, the brain and dementia: Neuroprotection or compensation? Brain 133, 2210-2216.
49. Meng X, D'ArcyC(2012) Education and dementia in the context of the cognitive reserve hypothesis: A systematic review with meta-Analyses and qualitative analyses. PLoS One 7, e38268.
50. Ngandu T, Strauss E, von, Helkala E-L, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M (2007) Education and dementia: What lies behind the association? Neurology 69, 1442-1450.
51. Sharp ES, Gatz M (2011) Relationship between education and dementia: An updated systematic review. Alzheimer Dis Assoc Disord 25, 289-304.
52. Stern Y (2009) Cognitive reserve. Neuropsychologia 47, 2015-2028.
53. Folstein MF, Folstein SE, McHugh PR (1975) 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
54. Kaplan E, Goodglass H, Weintraub S (1983) The Boston Naming Test, 2nd Ed., Lea & Febiger, Philadelphia.
55. Goodglass H, Kaplan E, Barresi B (2001) The Assessment of Aphasia and Related Disorders, Lippincott Williams & Wilkins.
56. WechslerD(1987) WMS-R:Wechsler Memory Scale-Revised, Psychological Corporation.
57. Wechsler D (1981) Wechsler Adult Intelligence Scale-Revised, Psychological Corporation.
58. Reitan R, Wolfson D (1993) The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Applications, Neuropsychology Press, Tucson, AZ.
59. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S (1982) Measurement of functional activities in older adults in the community. J Gerontol 37, 323-329.
60. Mirra S, Heyman A, McKeel D, Sumi S, Crain B, Brownlee L, Vogel M, Hughes M, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
61. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
62. Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the national institute on aging and the reagan instituteworking group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56, 1095-1097.
63. Muthen L, Muthen B (1998) Mplus User's Guide, Muthen & Muthen, Los Angeles.
64. Hu L, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equ Modeling 6, 1-55.
65. Iacobucci D (2010) Structural equations modeling: Fit Indices, sample size, and advanced topics. J Consum Psychol 20, 90-98.
66. Hayes AF (2009) Beyond Baron and Kenny: Statistical mediation analysis in the new millennium. Commun Monogr 76, 408-420.
67. MacKinnon D, Lockwood C, Williams J (2004) Confidence limits for the indirect effect: Distribution of the product and resampling methods. Multivariate Behav Res 39, 99-128.
68. Preacher KJ, Hayes AF (2008) Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods 40, 879-891.
69. Williams J, Mackinnon DP (2008) Resampling and distribution of the product methods for testing indirect effects in complex models. Struct Equ Modeling 15, 23-51.
70. Ho GJ, Hansen LA, AlfordMF, Foster K, SalmonDP, Galasko D, Thal LJ, Masliah E (2002) Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease. Neuroreport 13, 1825-1828.
71. Marshall G, Fairbanks L, Tekin S, Vinters HV, Cummings JL (2007) Early-onset Alzheimer's disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol 20, 29-33.
72. Royall DR, Palmer RF (2014) 'Executive functions' cannot be distinguished from general intelligence: Two variations on a single theme within a symphony of latent variance. Front Behav Neurosci 8, 369.
73. Eatough V, Shaw K, Lees A (2012) Banking on brains: Insights of brain donor relatives and friends from an experiential perspective. Psychol Health 27, 1271-1290.
74. Lambe S, Cantwell N, Islam F, Horvath K, Jefferson AL (2011) Perceptions, knowledge, incentives, and barriers of brain donation among African American elders enrolled in an Alzheimer's research program. Gerontologist 51, 28-38.
75. Jefferson AL, Lambe S, Cook E, Pimontel M, Palmisano J, Chaisson C (2011) Factors associated with African American and White elders' participation in a brain donation program. Alzheimer Dis Assoc Disord 25, 11-16.